Matthew T. Wiley

Matthew T. Wiley is a declared insider at 4 companies (senior executive); the most frequent names are Yarrow Bioscience, Inc., BioXcel Therapeutics, Inc. and Foamix Pharmaceuticals Ltd. Over a trading history stretching from 3 December 2018 to 25 September 2026, the count stands at 36 filings.

Both buying and selling appear: 1 purchase worth €45k, against 6 sales worth €219k. The net balance comes to €175k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 24 share grants and 3 option exercises. In 2026 alone, the filings show no purchases and 2 sales.

The latest filing, published on 29 September 2026, reports an open-market sale of €100k in Definium Therapeutics, Inc. The clock since the last published purchase (6 March 2019) now reads 2,788 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.